Media coverage about Rigel Pharmaceuticals (NASDAQ:RIGL) has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Rigel Pharmaceuticals earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.5180845433338 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
- Stocks In The NEWS -: QEP Resources, Inc. (NYSE:QEP), Aviragen Therapeutics, Inc. (NASDAQ:AVIR), Colony … – The Stock Street (press release) (thestreetpoint.com)
- Notable Investor’s Watch List: Atossa Genetics Inc., (NASDAQ: ATOS), Rigel Pharmaceuticals, Inc., (NASDAQ: RIGL … – Stocks In The News (press release) (tradingnewsnow.com)
- Rigel Pharmaceuticals, Inc. (RIGL) Raised to “Buy” at Zacks Investment Research (americanbankingnews.com)
- Rigel Pharmaceuticals, Inc. Expected to Post FY2017 Earnings of ($0.56) Per Share (RIGL) (americanbankingnews.com)
- EARNINGS SUMMARY: Details of Rigel Pharmaceuticals Inc. Q3 Earnings Report (rttnews.com)
A number of equities analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Rigel Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a research report on Saturday. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Rigel Pharmaceuticals in a research report on Monday, November 6th. Jefferies Group LLC reiterated a “buy” rating and set a $5.00 target price on shares of Rigel Pharmaceuticals in a research report on Wednesday, October 4th. BMO Capital Markets reiterated a “buy” rating and set a $5.00 target price on shares of Rigel Pharmaceuticals in a research report on Monday, October 2nd. Finally, ValuEngine upgraded shares of Rigel Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, October 2nd. Two research analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $5.31.
Rigel Pharmaceuticals (RIGL) opened at $3.74 on Wednesday. Rigel Pharmaceuticals has a 1 year low of $1.94 and a 1 year high of $4.33.
Rigel Pharmaceuticals (NASDAQ:RIGL) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.01. The firm had revenue of $0.90 million for the quarter. Rigel Pharmaceuticals had a negative net margin of 354.14% and a negative return on equity of 102.26%. The business’s quarterly revenue was down 76.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.24) EPS. research analysts forecast that Rigel Pharmaceuticals will post -0.58 earnings per share for the current year.
In other Rigel Pharmaceuticals news, CFO Ryan D. Maynard sold 100,000 shares of the company’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $3.90, for a total transaction of $390,000.00. Following the transaction, the chief financial officer now owns 100,000 shares in the company, valued at approximately $390,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 5.21% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Week Herald and is owned by of Week Herald. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://weekherald.com/2017/11/15/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-rigel-pharmaceuticals-rigl-stock-price.html.
About Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms.
Receive News & Ratings for Rigel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.